Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese
- Conditions
- Osteoporosis
- Registration Number
- NCT02166437
- Lead Sponsor
- Tomidahama Hospital
- Brief Summary
In this study, the investigators would like to analyze the bone mineral density (BMD) , bone turnover makers, and fracture prevention effects of bisphosphonate and denosumab randomly divided following daily teriparatide in Japanese patients under clinical practice. The participants are treated in the investigators hospital, who are under severe osteoporotic condition.
- Detailed Description
Registry criteria: Patients treated in the investigators hospital using teriparatide. Enrolled patients are severe osteoporosis; more than two previous osteoporotic fractures, low BMD (\< young adult mean 65%).
Interventions: blood analyses and dual-energy X-ray absorptiometry (DXA) every 4 months Informed consent: Written informed consent will be obtained. Sample size: Five-hundreds participants
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
- severe osteoporotic patients
- cancer, hypercalcemia, etc (i.e. patients who could not use bisphosphonate, denosmab, teriparatide)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical results of bisphosphonate vs. denosmab following daily teriparatide treatment Up to 36 months The investigators plan to analyze 500 patients who treated with bisphosphonate or denosmab following daily teriparatide treatment.
We investigate changes in BMD and bone turnover markers.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Tomidahama Hospital
🇯🇵Yokkaichi, Mie, Japan